印度对血友病A的基因疗法试验显示出有前途, 政府政策和合作伙伴推动了基于CRISPR的廉价安全治疗. India's gene therapy trial for Hemophilia A shows promise, with government policies and partnerships driving affordable, safe CRISPR-based treatments.

印度在基因编辑和细胞治疗方面取得了进展, 一个成功的血友病A基因疗法I期试验显示稳定 VIII 因素产生. India has made progress in gene-editing and cell therapy, with a successful Phase-I trial for Hemophilia A gene therapy showing stable Factor VIII production. 政府通过生物E3政策和CDSCO,ICMR和DBT的最新指南, 推动基于CRISPR的安全,伦理治疗方法. The government, through the BioE3 policy and updated guidelines from CDSCO, ICMR, and DBT, is advancing safe, ethical development of CRISPR-based treatments. 印度的CSIR-IGIB和血清研究所正在合作商业化治疗,而ICMR支持的研究加强了国内创新,基础设施和行业伙伴关系, 以确保负担得起,可访问的治疗方法并提高精确医学的自力更生. CSIR-IGIB and Serum Institute of India are collaborating to commercialize therapies, while ICMR-backed research strengthens domestic innovation, infrastructure, and industry partnerships to ensure affordable, accessible treatments and boost self-reliance in precision medicine.